The Wall Street Journal (8/13, Stynes, Subscription Publication, 5.33M) reports that Osiris Therapeutics’ Grafix stem-cell treatment was shown in a clinical study to have triple the effectiveness of conventional treatments in healing wounds from chronic diabetic foot ulcers. The flexible conforming membrane product closed wounds faster and reduced the number of treatments required, as well as proving to be safer than alternatives. Osiris plans to test Grafix for other uses such as venous leg ulcers.
Bloomberg News (8/14, Edney, 1.41M) reports interim results demonstrated 62% of Grafix users saw their wounds close completely. CEO C. Randla Mills boasted, “Osiris has established a new standard in diabetic wound care and has demonstrated to the world the tremendous impact stem cell products can have in medicine.” He noted that one-quarter of diabetics face foot ulcers.
Reuters (8/13, Ail) reports that Grafix delivers stem cells directly to a wound site and aids in regenerating tissues. All patients in the study will be put into the Grafix group.
The Washington Post (8/13, 4.53M) reports that the study was prompted by Osiris’ desire to broaden Medicare and insurance coverage for Grafix.
No comments:
Post a Comment